GB835638A
(en)
|
1956-12-01 |
1960-05-25 |
Novo Terapeutisk Labor As |
Insulin crystal suspensions having a protracted effect
|
GB840870A
(en)
|
1957-08-03 |
1960-07-13 |
Novo Terapeutisk Labor As |
Improvements in or relating to insulin preparations
|
JPS6033474B2
(ja)
|
1978-05-11 |
1985-08-02 |
藤沢薬品工業株式会社 |
新規なヒアルロニダ−ゼbmp−8231およびその製造法
|
PH25772A
(en)
|
1985-08-30 |
1991-10-18 |
Novo Industri As |
Insulin analogues, process for their preparation
|
CA1275922C
(en)
*
|
1985-11-28 |
1990-11-06 |
Harunobu Amagase |
Treatment of cancer
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
DK257988D0
(da)
|
1988-05-11 |
1988-05-11 |
Novo Industri As |
Nye peptider
|
DE3837825A1
(de)
|
1988-11-08 |
1990-05-10 |
Hoechst Ag |
Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
|
JPH04502465A
(ja)
|
1988-12-23 |
1992-05-07 |
ノボ ノルディスク アクティーゼルスカブ |
ヒトインシュリン類似物質
|
NZ232375A
(en)
|
1989-02-09 |
1992-04-28 |
Lilly Co Eli |
Insulin analogues modified at b29
|
CA2050911C
(en)
|
1989-05-04 |
1997-07-15 |
Thomas R. Tice |
Encapsulation process and products therefrom
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
DK155690D0
(da)
|
1990-06-28 |
1990-06-28 |
Novo Nordisk As |
Nye peptider
|
US5272135A
(en)
|
1991-03-01 |
1993-12-21 |
Chiron Ophthalmics, Inc. |
Method for the stabilization of methionine-containing polypeptides
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
DK0705275T3
(da)
|
1993-06-21 |
1999-09-20 |
Novo Nordisk As |
AspB28-insulin-krystaller
|
WO1995013799A1
(en)
|
1993-11-19 |
1995-05-26 |
Alkermes Controlled Therapeutics Inc. Ii |
Preparation of biodegradable microparticles containing a biologically active agent
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
JP2000516912A
(ja)
|
1996-06-05 |
2000-12-19 |
ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
エキセンジン類似体、それらの製造方法およびそれらを含有する製剤
|
DE19637230A1
(de)
|
1996-09-13 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
DE69737995T2
(de)
|
1996-06-20 |
2008-04-24 |
Novo Nordisk A/S |
INSULINPREPARATION MIT MAnnitol
|
UA49890C2
(uk)
*
|
1996-06-20 |
2002-10-15 |
Ново Нордіск А/С |
Водна інсулінова композиція, парентеральна фармацевтична композиція та спосіб поліпшення хімічної стабільності інсулінової композиції
|
US5948751A
(en)
*
|
1996-06-20 |
1999-09-07 |
Novo Nordisk A/S |
X14-mannitol
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
ES2319936T5
(es)
|
1996-08-08 |
2013-06-24 |
Amylin Pharmaceuticals, Inc. |
Regulación de la motilidad gastrointestinal
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
US6384016B1
(en)
|
1998-03-13 |
2002-05-07 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
WO1998030231A1
(en)
|
1997-01-07 |
1998-07-16 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the reduction of food intake
|
EP0981611A1
(en)
|
1997-02-05 |
2000-03-01 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
PE79099A1
(es)
*
|
1997-06-13 |
1999-08-24 |
Lilly Co Eli |
Formulaciones de insulina estables
|
EP0999853B1
(en)
|
1997-06-13 |
2003-01-02 |
Genentech, Inc. |
Stabilized antibody formulation
|
PT1019077E
(pt)
|
1997-08-08 |
2008-02-21 |
Amylin Pharmaceuticals Inc |
Novos compostos agonistas de exendina
|
CN1276731A
(zh)
|
1997-10-24 |
2000-12-13 |
伊莱利利公司 |
不溶性胰岛素组合物
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
EP1066314B1
(en)
|
1997-11-14 |
2007-12-26 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
BR9814189A
(pt)
|
1997-11-14 |
2000-10-03 |
Amylin Pharmaceuticals Inc |
"compostos agonistas da exendina"
|
JP2001525371A
(ja)
|
1997-12-05 |
2001-12-11 |
イーライ・リリー・アンド・カンパニー |
Glp−1製剤
|
CA2320371C
(en)
|
1998-02-13 |
2012-01-17 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and glp-1
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
IL138214A0
(en)
|
1998-03-09 |
2001-10-31 |
Zealand Pharmaceuticals As |
Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
EP1083930B1
(en)
|
1998-06-05 |
2008-11-12 |
Nutrinia Limited |
Insulin supplemented infant formula
|
DE69926007T2
(de)
|
1998-10-07 |
2005-12-29 |
Medical College Of Georgia Research Institute, Inc. |
Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
US6211144B1
(en)
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
US6489292B1
(en)
|
1998-11-18 |
2002-12-03 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
JP2007204498A
(ja)
|
1999-03-01 |
2007-08-16 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
BR0010705A
(pt)
|
1999-04-30 |
2002-02-05 |
Amylin Pharmaceuticals Inc |
Exendinas modificadas e agonistas da exendina
|
WO2000069911A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
DE19947456A1
(de)
|
1999-10-02 |
2001-04-05 |
Aventis Pharma Gmbh |
C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
|
HU227347B1
(en)
|
1999-10-04 |
2011-04-28 |
Novartis Vaccines & Diagnostic |
Stabilized liquid polypeptide-containing pharmaceutical compositions
|
JP2003519664A
(ja)
|
2000-01-11 |
2003-06-24 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1誘導体の経上皮送達
|
US20010012829A1
(en)
|
2000-01-11 |
2001-08-09 |
Keith Anderson |
Transepithelial delivery GLP-1 derivatives
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
AU2002248464A1
(en)
|
2001-02-21 |
2002-09-12 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
WO2002079250A1
(en)
|
2001-04-02 |
2002-10-10 |
Novo Nordisk A/S |
Insulin precursors and a process for their preparation
|
US7156877B2
(en)
|
2001-06-29 |
2007-01-02 |
The Regents Of The University Of California |
Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
|
MXPA04001560A
(es)
|
2001-08-28 |
2004-05-17 |
Lilly Co Eli |
Premezclas de glp-1 e insulina basal.
|
KR20040070237A
(ko)
|
2001-12-20 |
2004-08-06 |
일라이 릴리 앤드 캄파니 |
연장된 작용 시간을 갖는 인슐린 분자
|
WO2003066084A1
(en)
|
2002-02-07 |
2003-08-14 |
Novo Nordisk A/S |
Use of glp-1 compound for treatment of critically ill patients
|
ATE496064T1
(de)
|
2002-05-07 |
2011-02-15 |
Novo Nordisk As |
Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
|
JP2005526126A
(ja)
|
2002-05-07 |
2005-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
インスリンアスパルト及びインスリンデテミアを含む可溶性製剤
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
JP5685355B2
(ja)
|
2002-07-04 |
2015-03-18 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1および糖尿病の処置方法
|
CA2500295A1
(en)
|
2002-10-02 |
2004-04-29 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
WO2004080480A1
(en)
|
2003-03-11 |
2004-09-23 |
Novo Nordisk A/S |
Pharmaceutical preparations comprising acid-stabilised insulin
|
DE10325567B4
(de)
|
2003-06-05 |
2008-03-13 |
Mavig Gmbh |
Strahlenschutzanordnung mit separierbarer Umhüllung
|
JP5518282B2
(ja)
|
2003-09-01 |
2014-06-11 |
ノヴォ ノルディスク アー/エス |
安定なペプチドの製剤
|
WO2005028516A2
(en)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
EP1684793B1
(en)
|
2003-11-13 |
2011-09-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
|
US20050201978A1
(en)
|
2003-11-17 |
2005-09-15 |
Lipton James S. |
Tumor and infectious disease therapeutic compositions
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
US20080248999A1
(en)
|
2007-04-04 |
2008-10-09 |
Biodel Inc. |
Amylin formulations
|
US8673964B2
(en)
|
2004-05-20 |
2014-03-18 |
Diamedica Inc. |
Use of drug combinations for treating insulin resistance
|
US20060073213A1
(en)
|
2004-09-15 |
2006-04-06 |
Hotamisligil Gokhan S |
Reducing ER stress in the treatment of obesity and diabetes
|
WO2006029634A2
(en)
*
|
2004-09-17 |
2006-03-23 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
EP1817048B1
(en)
|
2004-11-12 |
2014-02-12 |
Novo Nordisk A/S |
Stable formulations of insulinoptropic peptides
|
US20090011976A1
(en)
|
2004-11-12 |
2009-01-08 |
Novo Nordisk A/S |
Stable Formulations Of Peptides
|
CN101060856B
(zh)
*
|
2004-11-22 |
2011-01-19 |
诺和诺德公司 |
可溶、稳定的含胰岛素制剂
|
DE102004058306A1
(de)
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
EP1849024A4
(en)
|
2005-02-01 |
2015-08-26 |
Canberra Ind Inc |
METHOD FOR DETECTING A MAXIMUM ENTROPY SIGNAL
|
EP1909824B1
(en)
|
2005-04-08 |
2011-05-18 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
|
EP1888118B1
(en)
|
2005-05-25 |
2016-08-17 |
Novo Nordisk A/S |
Polypeptide formulations stabilized with ethylenediamine
|
DK1888031T3
(da)
|
2005-06-06 |
2013-02-18 |
Camurus Ab |
GLP-1-analogformuleringer
|
DE102005046113A1
(de)
|
2005-09-27 |
2007-03-29 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
|
KR101105871B1
(ko)
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
WO2007044867A2
(en)
|
2005-10-11 |
2007-04-19 |
Huntington Medical Research Institutes |
Imaging agents and methods of use thereof
|
WO2007081824A2
(en)
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Fibrillation resistant proteins
|
WO2007082381A1
(en)
|
2006-01-20 |
2007-07-26 |
Diamedica Inc. |
Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
|
US20070191271A1
(en)
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
WO2007095288A2
(en)
|
2006-02-13 |
2007-08-23 |
Nektar Therapeutics |
Methionine-containing protein or peptide compositions and methods of making and using
|
US20090054305A1
(en)
|
2006-03-15 |
2009-02-26 |
Novo Nordisk A/S |
Mixtures of Amylin and Insulin
|
JP2009532422A
(ja)
|
2006-04-03 |
2009-09-10 |
ノボ・ノルデイスク・エー/エス |
Glp−1ペプチドアゴニスト
|
EP2015769A4
(en)
|
2006-04-13 |
2013-12-25 |
Ipsen Pharma |
PHARMACEUTICAL COMPOSITIONS OF HGLP-1, EXENDINE 4 AND THEIR ANALOGUES
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
CN101541830A
(zh)
|
2006-09-22 |
2009-09-23 |
诺沃-诺迪斯克有限公司 |
蛋白酶抗性的胰岛素类似物
|
JP5351884B2
(ja)
|
2007-04-23 |
2013-11-27 |
インターシア セラピューティクス,インコーポレイティド |
インスリン分泌促進性ペプチドの懸濁製剤及び使用
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
GB0717399D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
|
DK2219607T3
(da)
|
2007-11-01 |
2013-06-17 |
Merck Serono Sa |
Flydende LH-formuleringer
|
US8710000B2
(en)
*
|
2007-11-08 |
2014-04-29 |
Novo Nordisk A/S |
Insulin derivative
|
PT2597103T
(pt)
|
2007-11-16 |
2017-02-08 |
Novo Nordisk As |
Composições farmacêuticas contendo insulina e um péptido insulinotrófico
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
EP2231191A2
(en)
|
2007-12-11 |
2010-09-29 |
ConjuChem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
CA2711749A1
(en)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Novel insulin derivatives having an extremely delayed time-action profile
|
KR20100111683A
(ko)
|
2008-01-09 |
2010-10-15 |
사노피-아벤티스 도이칠란트 게엠베하 |
극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
KR100928942B1
(ko)
*
|
2008-05-26 |
2009-11-30 |
제이에스아이실리콘주식회사 |
직선형이나 고리형의 트리실라알칸의 제조방법
|
EP2684570A1
(en)
|
2008-09-10 |
2014-01-15 |
F. Hoffmann-La Roche AG |
Compositions and methods for the prevention of oxidative degradation of proteins
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
AU2009303905B2
(en)
|
2008-10-15 |
2015-01-22 |
Intarcia Therapeutics, Inc. |
Highly concentrated drug particles, formulations, suspensions and uses thereof
|
RS56632B1
(sr)
|
2008-10-17 |
2018-03-30 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
JP2009091363A
(ja)
|
2008-11-21 |
2009-04-30 |
Asahi Kasei Pharma Kk |
Pthの安定化水溶液注射剤
|
SG177567A1
(en)
|
2009-07-06 |
2012-02-28 |
Sanofi Aventis Deutschland |
Aqueous insulin preparations containing methionine
|
TW201105346A
(en)
|
2009-07-06 |
2011-02-16 |
Sanofi Aventis Deutschland |
Heat-stable and vibration-stable insulin preparations
|
EP2451471A1
(de)
|
2009-07-06 |
2012-05-16 |
Sanofi-Aventis Deutschland GmbH |
Langsamwirkende insulinzubereitungen
|
BR112012001988A2
(pt)
*
|
2009-07-31 |
2017-05-09 |
Sanofi Aventis Deutschland |
composição de insulina de ação prolongada
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
CN102711804B
(zh)
|
2009-11-13 |
2015-09-16 |
赛诺菲-安万特德国有限公司 |
包含glp-1激动剂和甲硫氨酸的药物组合物
|
AU2010317995B2
(en)
|
2009-11-13 |
2014-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
|
US20110118178A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
US20110118180A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
EP2389945A1
(en)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
JP6199186B2
(ja)
|
2010-08-30 |
2017-09-20 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病の治療用の医薬の製造のためのave0010の使用
|
JP2013545782A
(ja)
*
|
2010-12-14 |
2013-12-26 |
ノヴォ ノルディスク アー/エス |
長時間作用型インスリンと組み合わせた速効型インスリン
|
AU2012213435B2
(en)
|
2011-02-02 |
2017-03-30 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
BR112013029062A2
(pt)
|
2011-05-13 |
2016-11-29 |
Sanofi Aventis Deutschland |
lixisenatida e metformina para o tratamento de diabetes tipo 2
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
JP6367115B2
(ja)
|
2011-08-29 |
2018-08-01 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病患者の血糖コントロールに使用する組合せ医薬
|
ES2562651T3
(es)
|
2011-10-04 |
2016-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos
|
EP2763691A1
(en)
|
2011-10-04 |
2014-08-13 |
Sanofi-Aventis Deutschland GmbH |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
US20130296236A1
(en)
|
2011-10-28 |
2013-11-07 |
Louise SILVESTRE |
Treatment protocol of diabetes type 2
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
GB201303771D0
(en)
|
2013-03-04 |
2013-04-17 |
Midatech Ltd |
Nanoparticles peptide compositions
|
CN112957455A
(zh)
|
2014-01-09 |
2021-06-15 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
MX2016008978A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
|
CN105899190B
(zh)
|
2014-01-09 |
2022-06-14 |
赛诺菲 |
门冬胰岛素的稳定化药物制剂
|